Exclusive Summary

• World's First Monthly Administration: UB703 represents the world's first monthly GH-like treatment (GHR-targeted antibody) for AGHD, PGHD, and ISS, highlighting outstanding first-in-class potential.
• Overcoming Adherence Barriers: Transitioning from daily or weekly treatments to a highly convenient subcutaneous injection once a month comprehensively eliminates "injection fatigue" and markedly improves patient compliance, especially in pediatric populations.
• Unique & Superior PK/PD Profile: Preclinical and early Phase I adult data demonstrates lower Cmax (mitigating peak-related side effects) while establishing sustained and stable IGF-1 levels, optimally supporting long-term bone/overall growth.
• Compelling Turn-Key Out-Licensing Asset: Backed by clinically validated early PoC, its unrivaled dosing interval stands out against an expanding field of weekly therapies, making it a highly disruptive and valuable asset for global bio-pharma partners in endocrinology.

Asset Materials

Contact Us for Full Materials